OncXerna Revenue and Competitors
Estimated Revenue & Valuation
- OncXerna's estimated annual revenue is currently $2.2M per year.
- OncXerna's estimated revenue per employee is $201,000
Employee Data
- OncXerna has 11 Employees.
- OncXerna grew their employee count by -59% last year.
OncXerna's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Finance | Reveal Email/Phone |
2 | VP Program Management & Business Operations | Reveal Email/Phone |
3 | VP, Quality | Reveal Email/Phone |
4 | Senior Director, Global Clinical Operations | Reveal Email/Phone |
5 | Chief Development Officer & SVP Regulatory | Reveal Email/Phone |
6 | VP/ CMC | Reveal Email/Phone |
OncXerna Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is OncXerna?
Existing precision medicines target just 10 percent of cancers – those with gene mutations or oncogenic drivers for a small number of genes. Oncologie is ushering in a new era of precision medicine, leveraging the company's deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna Therapeutics applies its understanding of RNA signatures to describe the dominant biology of the patient's cancer and match it to therapies with mechanisms that modify the dominant biology to dramatically improve patient outcomes.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$2.2M
Revenue (est)
-59%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OncXerna News
OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian...
(OncXerna) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its...
Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 11 | -31% | $19.6M |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $0.9M | 11 | N/A | N/A |
#5 | $0.9M | 11 | -8% | $11.2M |